-
1 × 190,000UGX
-
1 × 6,300UGX
-
2 × 700UGX
-
1 × 45,000UGX
-
1 × 140,000UGX
-
1 × 80,000UGX
-
1 × 5,000UGX
-
1 × 400,000UGX
-
1 × 1,100UGX
-
1 × 1,500UGX
-
2 × 1,800UGX
-
1 × 100UGX
-
1 × 55,000UGX
-
1 × 1,400UGX
-
2 × 5,000UGX
-
1 × 4,000UGX
-
1 × 100,000UGX
-
1 × 215,000UGX
-
2 × 500UGX
-
1 × 350,000UGX
-
1 × 150,000UGX
-
1 × 2,500UGX
-
1 × 150,000UGX
-
1 × 15,000UGX
- Quantity of product Zinnat Tablet 250mg can not be less than 10
- Quantity of product Bismuth subgallate,bismuth oxide,zinc oxide ANUSOL SUPP 1's can not be less than 6
- Quantity of product Losartan 50mg & Hydrochlorothiazide 12.5mg Co-Losar Denk can not be less than 14
- Quantity of product Amlodipine 10mg Tablet AMLODAC10 10's can not be less than 10
- Quantity of product Nebivolol/ Hydrochlorothiazide Nebilong H Tablet 10's can not be less than 10
- Quantity of product Telvas H 80/12.5 Tablets 10's can not be less than 10
- Quantity of product Levofloxacin - 500 -LEVOBACT can not be less than 10
- Quantity of product Amlozaar Tablet 10's can not be less than 10
- Quantity of product Saxagliptin+Metformin 2.5/1000mg Kombiglyze XR Tablet pack of 60 can not be less than 10
- Quantity of product Magnesium 250/125mg MINT-O-COOL Tablets 10's can not be less than 100
- Quantity of product Bisoprolol 5mg CONCOR tablets 10's can not be less than 10
- Quantity of product Nifedipine 20mg NIFELAT R Tablets 10's can not be less than 10
- Quantity of product Amlodac 5 Tablets 10's can not be less than 14
- Quantity of product Clindamycin 300mg Dalacin C capsules 8's can not be less than 4
CA 19-9 (Pancreatic Cancer)
Roll over image to zoom in
75,000UGX
This test measures the amount of a protein called cancer antigen 19-9 (CA 19-9) in the blood helping to monitor the progress of pancreatic cancer treatment.
Blood.
No specific patient preparation protocol required. Inform the doctor if you are on any medications, have any allergies or underlying medical conditions before this test.
Cancer antigen 19-9 (CA 19-9) is a protein that exists on the surface of certain cancer cells. CA 19-9 does not cause cancer; rather, it is shed by the tumor cells and can be detected by laboratory tests in blood and sometimes other body fluids. CA 19-9 is elevated in about 70% to 95% of people with advanced pancreatic cancer. However, CA 19-9 may also be elevated in other cancers, conditions, and diseases such as: gallbladder and bile duct cancers (cholangiocarcinoma), colorectal cancer, gastric cancers, ovarian cancer, lung cancer, liver cancer, bile duct obstruction (e.g., gallstones), pancreatitis, cystic fibrosis, thyroid disease, and liver disease. Small amounts of CA 19-9 are present in the blood of healthy people. Since CA 19-9 is not specific for pancreatic cancer, it cannot be used by itself for screening or diagnosis.